Whole Exome Sequencing of Thymoma Patients Exhibiting Exceptional Responses to Pemetrexed Monotherapy

BACKGROUND Pemetrexed is used for the chemotherapy of advanced thymoma. Exceptional responses of thymoma to pemetrexed treatment are not frequently observed. The underlying genetic mechanism of the exceptional responses remains unclear. We used whole-exome sequencing to explore the specific genomic aberrations that lead to an extreme and durable response. METHODS Whole-exome sequencing using NovaSeq6000 (150 bp paired-end sequencing) was performed on nine formalin-fixed paraffin-embedded tissues from patients with advanced thymomas treated with pemetrexed (two exceptional responders and seven typical responders). RESULTS We identified 284 somatic single-nucleotide variants (SNVs; 272 missense, 8 missense/splice-site, 3 stop-gain, and 1 stop-gain/splice-site), 34 insertions and deletions (Indels; 33 frameshift and one splice region), and 21 copy number variations (CNVs; 15 gains and six losses). No difference in the number of SNVs variants and distribution of deleterious Indels was observed between the exceptional and typical responders. Interestingly, arm-level chromosomal CNVs (15 gains and six losses) were detected in four patients, including an exceptional responder. The highest number of arm-level CNVs was observed in an exceptional responder. CONCLUSION Exceptional responders to pemetrexed for metastatic thymomas may be characterized by arm-level CNVs. Further, whole-genome and RNA sequencing studies should be performed.

[1]  Hallie A. Swan,et al.  Extraordinary clinical response to ibrutinib in low-grade ovarian cancer guided by organoid drug testing , 2023, NPJ precision oncology.

[2]  R. L. Hollis,et al.  Whole exome sequencing of low grade serous ovarian carcinoma identifies genomic events associated with clinical outcome. , 2023, Gynecologic oncology.

[3]  C. Print,et al.  Chromosomal Aberrations Accumulate During Metastasis of Virus-negative Merkel Cell Carcinoma. , 2023, The Journal of investigative dermatology.

[4]  A. Kowalik,et al.  Molecular profiling of primary uveal melanoma: results of a Polish cohort , 2023, Melanoma research.

[5]  Jingsong He,et al.  The adverse impact of a gain in chromosome 1q on the prognosis of multiple myeloma treated with bortezomib-based regimens: A retrospective single-center study in China , 2022, Frontiers in Oncology.

[6]  Y. Ohya,et al.  STAT6 gain-of-function variant exacerbates multiple allergic symptoms. , 2022, The Journal of allergy and clinical immunology.

[7]  A. McPherson,et al.  Clonal somatic copy number altered driver events inform drug sensitivity in high-grade serous ovarian cancer , 2022, Nature Communications.

[8]  Larissa V Furtado,et al.  Prognostic significance of chromosome arm 1q gain and methylation class in molecularly defined diffuse leptomeningeal glioneuronal tumor , 2022, Acta Neuropathologica.

[9]  N. Girard,et al.  Comprehensive Genomic Profiling of 274 Thymic Epithelial Tumors Unveils Oncogenic Pathways and Predictive Biomarkers , 2022, The oncologist.

[10]  Xu Ma,et al.  Systematic review and meta-analysis of the predictive power of MTHFR polymorphisms for pemetrexed drug efficacy and toxicity in non-small cell lung cancer patients , 2021, Journal of chemotherapy.

[11]  C. Dieterich,et al.  Muscle‐specific Cand2 is translationally upregulated by mTORC1 and promotes adverse cardiac remodeling , 2021, EMBO reports.

[12]  J. Xing,et al.  Multiple‐level copy number variations in cell‐free DNA for prognostic prediction of HCC with radical treatments , 2021, Cancer science.

[13]  N. Phan,et al.  Comprehensive Analysis of Prognostic and Genetic Signatures for General Transcription Factor III (GTF3) in Clinical Colorectal Cancer Patients Using Bioinformatics Approaches , 2021, Current issues in molecular biology.

[14]  Min Hwan Kim,et al.  Genomic landscape of extraordinary responses in metastatic breast cancer , 2021, Communications Biology.

[15]  Yan Liu,et al.  Correction to: Human drug efflux transporter ABCC5 confers acquired resistance to pemetrexed in breast cancer , 2021, Cancer cell international.

[16]  Daoud M. Meerzaman,et al.  Molecular Profiling of Exceptional Responders to Cancer Therapy. , 2020, The oncologist.

[17]  Alina M. Hamilton,et al.  Molecular Features of Cancers Exhibiting Exceptional Responses to Treatment. , 2020, Cancer cell.

[18]  G. Sheu,et al.  BMI1-Mediated Pemetrexed Resistance in Non-Small Cell Lung Cancer Cells Is Associated with Increased SP1 Activation and Cancer Stemness , 2020, Cancers.

[19]  Ethan M. Goldberg,et al.  SCN3A‐Related Neurodevelopmental Disorder: A Spectrum of Epilepsy and Brain Malformation , 2020, Annals of neurology.

[20]  N. Yang,et al.  Concurrent ERBB2 missense mutations D769Y and D742 N Are Novel Acquired Mechanism of Gefitinib Resistance but Responds to Gefitinib plus Pyrotinib. , 2020, Lung cancer.

[21]  Da-ping Yu,et al.  Copy number variation in plasma as a tool for lung cancer prediction using Extreme Gradient Boosting (XGBoost) classifier , 2019, Thoracic cancer.

[22]  Nisha S Joseph,et al.  Gain of Chromosome 1q is associated with early progression in multiple myeloma patients treated with lenalidomide, bortezomib, and dexamethasone , 2019, Blood Cancer Journal.

[23]  J. Argente,et al.  LZTR1: Genotype Expansion in Noonan Syndrome , 2019, Hormone Research in Paediatrics.

[24]  K. Kurosawa,et al.  Diamond-Blackfan anemia caused by chromosome 1p22 deletion encompassing RPL5 , 2019, Human Genome Variation.

[25]  M. Shingyoji,et al.  AMPK activation induced in pemetrexed‐treated cells is associated with development of drug resistance independently of target enzyme expression , 2019, Molecular oncology.

[26]  B. Stricker,et al.  Prediction of response to pemetrexed in non-small-cell lung cancer with immunohistochemical phenotyping based on gene expression profiles , 2019, BMC Cancer.

[27]  Hui Shen,et al.  Detecting epistasis within chromatin regulatory circuitry reveals CAND2 as a novel susceptibility gene for obesity , 2019, International Journal of Obesity.

[28]  C. Yiannoutsos,et al.  A Phase II Study of Pemetrexed in Patients with Recurrent Thymoma and Thymic Carcinoma , 2018, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[29]  Q. Wang,et al.  Thymidylate synthase predicts poor response to pemetrexed chemotherapy in patients with advanced breast cancer. , 2018, Oncology letters.

[30]  Yankai Xia,et al.  Identification of two novel PCDHA9 mutations associated with Hirschsprung's disease. , 2018, Gene.

[31]  Yuan-ming Pan,et al.  A Novel Method to Detect Early Colorectal Cancer Based on Chromosome Copy Number Variation in Plasma , 2018, Cellular Physiology and Biochemistry.

[32]  Benjamin J. Raphael,et al.  The Integrated Genomic Landscape of Thymic Epithelial Tumors. , 2018, Cancer cell.

[33]  F. Wang,et al.  GTF2I mutation frequently occurs in more indolent thymic epithelial tumors and predicts better prognosis. , 2017, Lung cancer.

[34]  Michael T. Zimmermann,et al.  Functional validation reveals the novel missense V419L variant in TGFBR2 associated with Loeys–Dietz syndrome (LDS) impairs canonical TGF-β signaling , 2017, Cold Spring Harbor molecular case studies.

[35]  T. Oguri,et al.  A folylpoly-γ-glutamate synthase single nucleotide polymorphism associated with response to pemetrexed treatment combined with platinum for non-small cell lung cancer. , 2016, Lung cancer.

[36]  Z. Song,et al.  Efficacy of pemetrexed-based regimen in relapsed advanced thymic epithelial tumors and its association with thymidylate synthetase level , 2016, OncoTargets and therapy.

[37]  Y. Hirose,et al.  World Health Organization grade II–III astrocytomas consist of genetically distinct tumor lineages , 2016, Cancer science.

[38]  Eric Talevich,et al.  CNVkit: Genome-Wide Copy Number Detection and Visualization from Targeted DNA Sequencing , 2016, PLoS Comput. Biol..

[39]  In Seok Yang,et al.  Next-generation sequencing reveals somatic mutations that confer exceptional response to everolimus , 2016, Oncotarget.

[40]  C. Sarkar,et al.  Evaluation of chromosome 1q gain in intracranial ependymomas , 2016, Journal of Neuro-Oncology.

[41]  R. Toyozawa,et al.  Are Anthracycline‐Based Regimens Truly Indicated To Be the Standard Chemotherapy Regimen for Thymic Carcinoma? , 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[42]  M. Babron,et al.  Homozygous STIL Mutation Causes Holoprosencephaly and Microcephaly in Two Siblings , 2015, PloS one.

[43]  A. Torkamani,et al.  ASXL1 and DNMT3A mutation in a cytogenetically normal B3 thymoma , 2014, Oncogenesis.

[44]  Jaime Rodriguez-Canales,et al.  A specific missense mutation in GTF2I occurs at high frequency in thymic epithelial tumors , 2014, Nature Genetics.

[45]  S. Gabriel,et al.  Activating mTOR mutations in a patient with an extraordinary response on a phase I trial of everolimus and pazopanib. , 2014, Cancer discovery.

[46]  James R. Anderson,et al.  Gain of 1q is associated with inferior event‐free and overall survival in patients with favorable histology Wilms tumor: A report from the Children's Oncology Group , 2013, Cancer.

[47]  Yi-Song Wang,et al.  Whole Genome and Transcriptome Sequencing of a B3 Thymoma , 2013, PloS one.

[48]  Y. Kanda,et al.  Investigation of the freely available easy-to-use software ‘EZR' for medical statistics , 2012, Bone Marrow Transplantation.

[49]  Kristian Cibulskis,et al.  A homozygous missense mutation in HERC2 associated with global developmental delay and autism spectrum disorder , 2012, Human mutation.

[50]  Steven J. M. Jones,et al.  Comprehensive molecular characterization of human colon and rectal cancer , 2012, Nature.

[51]  P. Meltzer,et al.  Copy number aberrations of BCL2 and CDKN2A/B identified by array-CGH in thymic epithelial tumors , 2012, Cell Death and Disease.

[52]  Joshua F. McMichael,et al.  Whole Genome Analysis Informs Breast Cancer Response to Aromatase Inhibition , 2012, Nature.

[53]  Christopher A. Miller,et al.  VarScan 2: somatic mutation and copy number alteration discovery in cancer by exome sequencing. , 2012, Genome research.

[54]  T. Löning,et al.  Studies of genomic imbalances and the MYB-NFIB gene fusion in polymorphous low-grade adenocarcinoma of the head and neck. , 2011, International journal of oncology.

[55]  L. Benesova,et al.  Extraordinary response to erlotinib therapy in a patient with lung adenocarcinoma exhibiting KRAS mutation and EGFR amplification. , 2011, Cancer genomics & proteomics.

[56]  A. Sparks,et al.  The mutation spectrum revealed by paired genome sequences from a lung cancer patient , 2010, Nature.

[57]  N. Girard,et al.  Comprehensive Genomic Analysis Reveals Clinically Relevant Molecular Distinctions between Thymic Carcinomas and Thymomas , 2009, Clinical Cancer Research.

[58]  R. Sinke,et al.  An amino-terminal DAX1 (NROB1) missense mutation associated with isolated mineralocorticoid deficiency. , 2007, The Journal of clinical endocrinology and metabolism.

[59]  Sachin R. Shah,et al.  Pemetrexed, a Novel Antifolate Therapeutic Alternative for Cancer Chemotherapy , 2006, Pharmacotherapy.

[60]  Alexander A Morley,et al.  Evidence for whole chromosome 6 loss and duplication of the remaining chromosome in acute lymphoblastic leukemia , 2003, Genes, chromosomes & cancer.

[61]  H. Müller-Hermelink,et al.  Chromosome 6 suffers frequent and multiple aberrations in thymoma. , 2002, The American journal of pathology.

[62]  O. Larsson,et al.  Concomitant loss of chromosome 3 and whole arm losses and gains of chromosome 1, 6, or 8 in metastasizing primary uveal melanoma. , 2001, Investigative ophthalmology & visual science.

[63]  A. Rosenwald,et al.  Recurrent genetic aberrations in thymoma and thymic carcinoma. , 2000, The American journal of pathology.

[64]  M. Chen,et al.  Cisplatin, doxorubicin, and cyclophosphamide plus thoracic radiation therapy for limited-stage unresectable thymoma: an intergroup trial. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[65]  J. Pedersen‐Bjergaard,et al.  Different genetic pathways in leukemogenesis for patients presenting with therapy-related myelodysplasia and therapy-related acute myeloid leukemia. , 1995, Blood.

[66]  L. Schwartz,et al.  New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). , 2009, European journal of cancer.